Vessix Vascular Acquired By Boston Scientific For $425M

Laguna Hills-based Vessix Vascular, a deveveloper of percutaneous radiofrequency (RF) balloon catheter technology being targeted at treating hypertension, has been acquired by Boston Scientific Corporation, the two said this morning. The deal is worth an aggregate value of $425M, and includes $125M in an upfront playment plus up to $300M tied to clinical and sales-based milestones. Vessix becomes part of Boston Scientific's Peripheral Interventions business. Vessix Vascular was venture backed by CDF Dinova Venture Partners, Christopher Weil & Company, Edmond de Rothschild Investment Partners, Neomed Management, and Orbimed Advisors. The company had raised somewhere north of $38M in funding.